Emerging concepts: mast cell involvement in allergic diseases

Translational Research

Volumn 174, Issue , 2016, Pages 98-121

  Modena, Brian D ^a,b   Dazy, Kristen ^a   White, Andrew A ^a  

^a SCRIPPS CLINIC   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PEPTIDERGIC DRUG; UNCLASSIFIED DRUG; VANCOMYCIN;

AIRWAY REMODELING; ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ALLERGIC REACTION; ALLERGIC RHINITIS; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; ATOPIC DERMATITIS; CHRONIC RHINOSINUSITIS; HUMAN; INNATE IMMUNITY; MAST CELL; NONHUMAN; NOSE POLYP; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; ANIMAL; DRUG HYPERSENSITIVITY; HYPERSENSITIVITY; IMMUNOLOGY; PATHOLOGY;

AIRWAY REMODELING; ANIMALS; DRUG HYPERSENSITIVITY; HUMANS; HYPERSENSITIVITY; IMMUNITY, INNATE; MAST CELLS;

EID: 84982219421     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2016.02.011     Document Type: Review

References (307)

1. 1 Nakano, T., Sonoda, T., Hayashi, C., et al. Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell-deficient W/Wv mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells. J Exp Med 162 (1985), 1025–1043.
2. 2 Marshall, J.S., Mast-cell responses to pathogens. Nat Rev Immunol 4 (2004), 787–799.
3. 3 Galli, S.J., Zsebo, K.M., Geissler, E.N., The kit ligand, stem cell factor. Adv Immunol 55 (1994), 1–96.
4. 4 Oliveira, S.H., Lukacs, N.W., Stem cell factor: a hemopoietic cytokine with important targets in asthma. Curr Drug Targets Inflamm Allergy 2 (2003), 313–318.
5. 5 Reber, L., Da Silva, C.A., Frossard, N., Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 533 (2006), 327–340.
6. 6 Sillaber, C., Strobl, H., Bevec, D., et al. IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J Immunol 147 (1991), 4224–4228.
7. 7 Toru, H., Eguchi, M., Matsumoto, R., Yanagida, M., Yata, J., Nakahata, T., Interleukin-4 promotes the development of tryptase and chymase double-positive human mast cells accompanied by cell maturation. Blood 91 (1998), 187–195.
8. 8 Toru, H., Ra, C., Nonoyama, S., Suzuki, K., Yata, J., Nakahata, T., Induction of the high-affinity IgE receptor (Fc epsilon RI) on human mast cells by IL-4. Int Immunol 8 (1996), 1367–1373.
9. 9 Valent, P., Bevec, D., Maurer, D., et al. Interleukin 4 promotes expression of mast cell ICAM-1 antigen. Proc Natl Acad Sci U S A 88 (1991), 3339–3342.
10. 10 Matsuzawa, S., Sakashita, K., Kinoshita, T., Ito, S., Yamashita, T., Koike, K., IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol 170 (2003), 3461–3467.
11. 11 Mwamtemi, H.H., Koike, K., Kinoshita, T., et al. An increase in circulating mast cell colony-forming cells in asthma. J Immunol 166 (2001), 4672–4677.
12. 12 Bailey, D.P., Kashyap, M., Bouton, L.A., Murray, P.J., Ryan, J.J., Interleukin-10 induces apoptosis in developing mast cells and macrophages. J Leukoc Biol 80 (2006), 581–589.
13. 13 Royer, B., Varadaradjalou, S., Saas, P., Guillosson, J.J., Kantelip, J.P., Arock, M., Inhibition of IgE-induced activation of human mast cells by IL-10. Clin Exp Allergy 31 (2001), 694–704.
14. 14 Yeatman, C.F. 2nd, Jacobs-Helber, S.M., Mirmonsef, P., et al. Combined stimulation with the T helper cell type 2 cytokines interleukin (IL)-4 and IL-10 induces mouse mast cell apoptosis. J Exp Med 192 (2000), 1093–1103.
15. 15 Ho, L.H., Ohno, T., Oboki, K., et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol 82 (2007), 1481–1490.
16. 16 Iikura, M., Suto, H., Kajiwara, N., et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 87 (2007), 971–978.
17. 17 Godot, V., Arock, M., Garcia, G., et al. H4 histamine receptor mediates optimal migration of mast cell precursors to CXCL12. J Allergy Clin Immunol 120 (2007), 827–834.
18. 18 Lin, T.J., Issekutz, T.B., Marshall, J.S., Human mast cells transmigrate through human umbilical vein endothelial monolayers and selectively produce IL-8 in response to stromal cell-derived factor-1 alpha. J Immunol 165 (2000), 211–220.
19. 19 Macey, M.R., Sturgill, J.L., Morales, J.K., et al. IL-4 and TGF-beta 1 counterbalance one another while regulating mast cell homeostasis. J Immunol 184 (2010), 4688–4695.
20. 20 Matsuda, H., Kannan, Y., Ushio, H., et al. Nerve growth factor induces development of connective tissue-type mast cells in vitro from murine bone marrow cells. J Exp Med 174 (1991), 7–14.
21. 21 Cruse, G., Bradding, P., Mast cells in airway diseases and interstitial lung disease. Eur J Pharmacol 778 (2016), 125–138.
22. 22 Cheng, L.E., Hartmann, K., Roers, A., Krummel, M.F., Locksley, R.M., Perivascular mast cells dynamically probe cutaneous blood vessels to capture immunoglobulin E. Immunity 38 (2013), 166–175.
23. 23 St John, A.L., Abraham, S.N., Innate immunity and its regulation by mast cells. J Immunol 190 (2013), 4458–4463.
24. 24 Abraham, S.N., St John, A.L., Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 10 (2010), 440–452.
25. 25 Hofmann, A.M., Abraham, S.N., New roles for mast cells in modulating allergic reactions and immunity against pathogens. Curr Opin Immunol 21 (2009), 679–686.
26. 26 Galli, S.J., Maurer, M., Lantz, C.S., Mast cells as sentinels of innate immunity. Curr Opin Immunol 11 (1999), 53–59.
27. 27 Shikhagaie, M.M., Andersson, C.K., Mori, M., et al. Mapping of TLR5 and TLR7 in central and distal human airways and identification of reduced TLR expression in severe asthma. Clin Exp Allergy 44 (2014), 184–196.
28. 28 Persson, C.G., Erjefält, J.S., Greiff, L., et al. Plasma-derived proteins in airway defence, disease and repair of epithelial injury. Eur Respir J 11 (1998), 958–970.
29. 29 McDonald, D.M., Thurston, G., Baluk, P., Endothelial gaps as sites for plasma leakage in inflammation. Microcirculation 6 (1999), 7–22.
30. 30 Heissig, B., Rafii, S., Akiyama, H., et al. Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization. J Exp Med 202 (2005), 739–750.
31. 31 Weller, K., Foitzik, K., Paus, R., Syska, W., Maurer, M., Mast cells are required for normal healing of skin wounds in mice. FASEB J 20 (2006), 2366–2368.
32. 32 Metz, M., Maurer, M., Mast cells–key effector cells in immune responses. Trends Immunol 28 (2007), 234–241.
33. 33 Galli, S.J., Kalesnikoff, J., Grimbaldeston, M.A., Piliponsky, A.M., Williams, C.M., Tsai, M., Mast cells as “tunable” effector and immunoregulatory cells: recent advances. Annu Rev Immunol 23 (2005), 749–786.
34. 34 Ishizuka, T., Okayama, Y., Kobayashi, H., Mori, M., Interleukin-10 is localized to and released by human lung mast cells. Clin Exp Allergy 29 (1999), 1424–1432.
35. 35 Piliponsky, A.M., Chen, C.C., Rios, E.J., et al. The chymase mouse mast cell protease 4 degrades TNF, limits inflammation, and promotes survival in a model of sepsis. Am J Pathol 181 (2012), 875–886.
36. 36 Waern, I., Karlsson, I., Thorpe, M., et al. Mast cells limit extracellular levels of IL-13 via a serglycin proteoglycan-serine protease axis. Biol Chem 393 (2012), 1555–1567.
37. 37 Irani, A.M., Butrus, S.I., Tabbara, K.F., Schwartz, L.B., Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis. J Allergy Clin Immunol 86 (1990), 34–40.
38. 38 Amin, K., The role of mast cells in allergic inflammation. Respir Med 106 (2012), 9–14.
39. 39 Brandt, E.B., Strait, R.T., Hershko, D., et al. Mast cells are required for experimental oral allergen-induced diarrhea. J Clin Invest 112 (2003), 1666–1677.
40. 40 Hart, P.H., Regulation of the inflammatory response in asthma by mast cell products. Immunol Cell Biol 79 (2001), 149–153.
41. 41 Marone, G., Triggiani, M., de Paulis, A., Mast cells and basophils: friends as well as foes in bronchial asthma?. Trends Immunol 26 (2005), 25–31.
42. 42 Brightling, C.E., Symon, F.A., Birring, S.S., Bradding, P., Wardlaw, A.J., Pavord, I.D., Comparison of airway immunopathology of eosinophilic bronchitis and asthma. Thorax 58 (2003), 528–532.
43. 43 Brightling, C.E., Bradding, P., Symon, F.A., Holgate, S.T., Wardlaw, A.J., Pavord, I.D., Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 346:22 (2002), 1699–1705.
44. 44 Cho, E.Y., Choi, S.C., Lee, S.H., et al. Nafamostat mesilate attenuates colonic inflammation and mast cell infiltration in the experimental colitis. Int Immunopharmacol 11 (2011), 412–417.
45. 45 Raithel, M., Winterkamp, S., Pacurar, A., Ulrich, P., Hochberger, J., Hahn, E.G., Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease. Scand J Gastroenterol 36 (2001), 174–179.
46. 46 Betts, C.J., Else, K.J., Mast cells, eosinophils and antibody-mediated cellular cytotoxicity are not critical in resistance to Trichuris muris. Parasite Immunol 21 (1999), 45–52.
47. 47 Lantz, C.S., Boesiger, J., Song, C.H., et al. Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature 392 (1998), 90–93.
48. 48 Edwards, S.T., Cruz, A.C., Donnelly, S., et al. c-Kit immunophenotyping and metalloproteinase expression profiles of mast cells in interstitial lung diseases. J Pathol 206 (2005), 279–290.
49. 49 Kawanami, O., Ferrans, V.J., Fulmer, J.D., Crystal, R.G., Ultrastructure of pulmonary mast cells in patients with fibrotic lung disorders. Lab Invest 40 (1979), 717–734.
50. 50 Yoshizaki, A., Iwata, Y., Komura, K., et al. CD19 regulates skin and lung fibrosis via toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 172 (2008), 1650–1663.
51. 51 Reber, L.L., Daubeuf, F., Pejler, G., Abrink, M., Frossard, N., Mast cells contribute to bleomycin-induced lung inflammation and injury in mice through a chymase/mast cell protease 4-dependent mechanism. J Immunol 192 (2014), 1847–1854.
52. 52 Reber, L.L., Sibilano, R., Mukai, K., Galli, S.J., Potential effector and immunoregulatory functions of mast cells in mucosal immunity. Mucosal Immunol 8 (2015), 444–463.
53. 53 Papadimitriou, J.C., Drachenberg, C.B., Ramos, E., Ugarte, R., Haririan, A., Mast cell quantitation in renal transplant biopsy specimens as a potential marker for the cumulative burden of tissue injury. Transplant Proc 45 (2013), 1469–1471.
54. 54 Enerback, L., Mast cells in rat gastrointestinal mucosa. I. Effects of fixation. Acta Pathol Microbiol Scand 66 (1966), 289–302.
55. 55 Irani, A.M., Schwartz, L.B., Mast cell heterogeneity. Clin Exp Allergy 19 (1989), 143–155.
56. 56 Erjefalt, J.S., Mast cells in human airways: the culprit?. Eur Respir Rev 23 (2014), 299–307.
57. 57 Irani, A.M., Goldstein, S.M., Wintroub, B.U., Bradford, T., Schwartz, L.B., Human mast cell carboxypeptidase. Selective localization to MCTC cells. J Immunol 147 (1991), 247–253.
58. 58 Irani, A.A., Schechter, N.M., Craig, S.S., DeBlois, G., Schwartz, L.B., Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci U S A 83 (1986), 4464–4468.
59. 59 Irani, A.M., Bradford, T.R., Kepley, C.L., Schechter, N.M., Schwartz, L.B., Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J Histochem Cytochem 37 (1989), 1509–1515.
60. 60 Schechter, N.M., Irani, A.M., Sprows, J.L., Abernethy, J., Wintroub, B., Schwartz, L.B., Identification of a cathepsin G-like proteinase in the MCTC type of human mast cell. J Immunol 145 (1990), 2652–2661.
61. 61 Caughey, G.H., Raymond, W.W., Blount, J.L., et al. Characterization of human gamma-tryptases, novel members of the chromosome 16p mast cell tryptase and prostasin gene families. J Immunol 164 (2000), 6566–6575.
62. 62 Wong, G.W., Tang, Y., Feyfant, E., et al. Identification of a new member of the tryptase family of mouse and human mast cell proteases which possesses a novel COOH-terminal hydrophobic extension. J Biol Chem 274 (1999), 30784–30793.
63. 63 Xia, H.Z., Kepley, C.L., Sakai, K., Chelliah, J., Irani, A.M., Schwartz, L.B., Quantitation of tryptase, chymase, Fc epsilon RI alpha, and Fc epsilon RI gamma mRNAs in human mast cells and basophils by competitive reverse transcription-polymerase chain reaction. J Immunol 154 (1995), 5472–5480.
64. 64 Weidner, N., Austen, K.F., Heterogeneity of mast cells at multiple body sites. Fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content. Pathol Res Pract 189 (1993), 156–162.
65. 65 Fajt, M.L., Wenzel, S.E., Mast cells, their subtypes, and relation to asthma phenotypes. Ann Am Thorac Soc 10:Suppl (2013), S158–S164.
66. 66 Matin, R., Tam, E.K., Nadel, J.A., Caughey, G.H., Distribution of chymase-containing mast cells in human bronchi. J Histochem Cytochem 40 (1992), 781–786.
67. 67 Andersson, C.K., Mori, M., Bjermer, L., Löfdahl, C.G., Erjefält, J.S., Novel site-specific mast cell subpopulations in the human lung. Thorax 64 (2009), 297–305.
68. 68 Hayes, S.M., Howlin, R., Johnston, D.A., et al. Intracellular residency of Staphylococcus aureus within mast cells in nasal polyps: a novel observation. J Allergy Clin Immunol 135 (2015), 1648–1651.
69. 69 Casale, T.B., Wood, D., Richerson, H.B., et al. Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with methacholine bronchial hyperresponsiveness. J Clin Invest 79 (1987), 1197–1203.
70. 70 Wenzel, S.E., Fowler, A.A. 3rd, Schwartz, L.B., Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma. Am Rev Respir Dis 137 (1988), 1002–1008.
71. 71 Wenzel, S.E., Westcott, J.Y., Larsen, G.L., Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic responses. J Allergy Clin Immunol 87 (1991), 540–548.
72. 72 Murray, J.J., Tonnel, A.B., Brash, A.R., et al. Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med 315 (1986), 800–804.
73. 73 Beasley, R., Varley, J., Robinson, C., Holgate, S.T., Cholinergic-mediated bronchoconstriction induced by prostaglandin D2, its initial metabolite 9 alpha,11 beta-PGF2, and PGF2 alpha in asthma. Am Rev Respir Dis 136 (1987), 1140–1144.
74. 74 Wenzel, S.E., Larsen, G.L., Johnston, K., Voelkel, N.F., Westcott, J.Y., Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 142 (1990), 112–119.
75. 75 Chhabra, J., Li, Y.Z., Alkhouri, H., et al. Histamine and tryptase modulate asthmatic airway smooth muscle GM-CSF and RANTES release. Eur Respir J 29 (2007), 861–870.
76. 76 Jarjour, N.N., Calhoun, W.J., Schwartz, L.B., Busse, W.W., Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with increased airway obstruction. Am Rev Respir Dis 144 (1991), 83–87.
77. 77 Sekizawa, K., Caughey, G.H., Lazarus, S.C., Gold, W.M., Nadel, J.A., Mast cell tryptase causes airway smooth muscle hyperresponsiveness in dogs. J Clin Invest 83 (1989), 175–179.
78. 78 Tam, E.K., Caughey, G.H., Degradation of airway neuropeptides by human lung tryptase. Am J Respir Cell Mol Biol 3 (1990), 27–32.
79. 79 Franconi, G.M., Graf, P.D., Lazarus, S.C., Nadel, J.A., Caughey, G.H., Mast cell tryptase and chymase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the ferret. J Pharmacol Exp Ther 248 (1989), 947–951.
80. 80 Tam, E.K., Franconi, G.M., Nadel, J.A., Caughey, G.H., Protease inhibitors potentiate smooth muscle relaxation induced by vasoactive intestinal peptide in isolated human bronchi. Am J Respir Cell Mol Biol 2 (1990), 449–452.
81. 81 Christie, P.E., Spur, B.W., Lee, T.H., The effects of lipoxin A4 on airway responses in asthmatic subjects. Am Rev Respir Dis 145 (1992), 1281–1284.
82. 82 Clague, H., Ahmad, D., Chamberlain, M.J., Morgan, W.K., Vinitski, S., Histamine bronchial challenge: effect on regional ventilation and aerosol deposition. Thorax 38 (1983), 668–675.
83. 83 du Toit, J.I., Anderson, S.D., Jenkins, C.R., Woolcock, A.J., Rodwell, L.T., Airway responsiveness in asthma: bronchial challenge with histamine and 4.5% sodium chloride before and after budesonide. Allergy Asthma Proc 18 (1997), 7–14.
84. 84 Sampson, S.E., Sampson, A.P., Costello, J.F., Effect of inhaled prostaglandin D2 in normal and atopic subjects, and of pretreatment with leukotriene D4. Thorax 52 (1997), 513–518.
85. 85 Rafferty, P., Holgate, S.T., Terfenadine (Seldane) is a potent and selective histamine H1 receptor antagonist in asthmatic airways. Am Rev Respir Dis 135 (1987), 181–184.
86. 86 Curzen, N., Rafferty, P., Holgate, S.T., Effects of a cyclo-oxygenase inhibitor, flurbiprofen, and an H1 histamine receptor antagonist, terfenadine, alone and in combination on allergen induced immediate bronchoconstriction in man. Thorax 42 (1987), 946–952.
87. 87 Taylor, I.K., O'Shaughnessy, K.M., Fuller, R.W., Dollery, C.T., Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 337 (1991), 690–694.
88. 88 Findlay, S.R., Barden, J.M., Easley, C.B., Glass, M., Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 89 (1992), 1040–1045.
89. 89 Boulet, L.P., Chapman, K.R., Cote, J., et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 155 (1997), 1835–1840.
90. 90 Fahy, J.V., Fleming, H.E., Wong, H.H., et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155 (1997), 1828–1834.
91. 91 Cockcroft, D.W., Ruffin, R.E., Dolovich, J., Hargreave, F.E., Allergen-induced increase in non-allergic bronchial reactivity. Clin Allergy 7 (1977), 503–513.
92. 92 Bentley, A.M., Meng, Q., Robinson, D.S., Hamid, Q., Kay, A.B., Durham, S.R., Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am J Respir Cell Mol Biol 8 (1993), 35–42.
93. 93 De Monchy, J.G., Kauffman, H.F., Venge, P., et al. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis 131 (1985), 373–376.
94. 94 Diaz, P., Gonzalez, M.C., Galleguillos, F.R., et al. Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late-phase asthmatic reactions. Am Rev Respir Dis 139 (1989), 1383–1389.
95. 95 Metzger, W.J., Zavala, D., Richerson, H.B., et al. Local allergen challenge and bronchoalveolar lavage of allergic asthmatic lungs. Description of the model and local airway inflammation. Am Rev Respir Dis 135 (1987), 433–440.
96. 96 Montefort, S., Gratziou, C., Goulding, D., et al. Bronchial biopsy evidence for leukocyte infiltration and upregulation of leukocyte-endothelial cell adhesion molecules 6 hours after local allergen challenge of sensitized asthmatic airways. J Clin Invest 93 (1994), 1411–1421.
97. 97 Tonnel, A.B., Joseph, M., Gosset, P., Fournier, E., Capron, A., Stimulation of alveolar macrophages in asthmatic patients after local provocation test. Lancet 1 (1983), 1406–1408.
98. 98 Schwartz, L.B., Tryptase, a mediator of human mast cells. J Allergy Clin Immunol 86:4 Pt 2 (1990), 594–598.
99. 99 Ruoss, S.J., Hartmann, T., Caughey, G.H., Mast cell tryptase is a mitogen for cultured fibroblasts. J Clin Invest 88 (1991), 493–499.
100. 100 Gruber, B.L., Kew, R.R., Jelaska, A., et al. Human mast cells activate fibroblasts: tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis. J Immunol 158 (1997), 2310–2317.
101. 101 Berger, P., Perng, D.-W., Thabrew, H., et al. Tryptase and agonists of PAR-2 induce the proliferation of human airway smooth muscle cells. J Appl Physiol 91 (2001), 1372–1379.
102. 102 Cairns, J.A., Walls, A.F., Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J Clin Invest 99 (1997), 1313–1321.
103. 103 Panettieri, R.A., Yadvish, P.A., Kelly, A.M., Rubinstein, N.A., Kotlikoff, M.I., Histamine stimulates proliferation of airway smooth muscle and induces c-fos expression. Am J Physiol 259:6 Pt 1 (1990), L365–L371.
104. 104 Borthwick, L.A., Wynn, T.A., Fisher, A.J., Cytokine mediated tissue fibrosis. Biochim Biophys Acta 1832 (2013), 1049–1060.
105. 105 Bradding, P., Walls, A.F., Holgate, S.T., The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 117 (2006), 1277–1284.
106. 106 Dvorak, A.M., Tepper, R.I., Weller, P.F., et al. Piecemeal degranulation of mast cells in the inflammatory eyelid lesions of interleukin-4 transgenic mice. Evidence of mast cell histamine release in vivo by diamine oxidase-gold enzyme-affinity ultrastructural cytochemistry. Blood 83 (1994), 3600–3612.
107. 107 Theoharides, T.C., Kempuraj, D., Tagen, M., Conti, P., Kalogeromitros, D., Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 217 (2007), 65–78.
108. 108 Kanoh, S., Tanabe, T., Rubin, B.K., IL-13-induced MUC5AC production and goblet cell differentiation is steroid resistant in human airway cells. Clin Exp Allergy 41 (2011), 1747–1756.
109. 109 Licona-Limon, P., Kim, L.K., Palm, N.W., Flavell, R.A., TH2, allergy and group 2 innate lymphoid cells. Nat Immunol 14 (2013), 536–542.
110. 110 Chatila, T.A., Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trends Mol Med 10 (2004), 493–499.
111. 111 Fish, S.C., Donaldson, D.D., Goldman, S.J., Williams, C.M., Kasaian, M.T., IgE generation and mast cell effector function in mice deficient in IL-4 and IL-13. J Immunol 174 (2005), 7716–7724.
112. 112 Grunig, G., Warnock, M., Wakil, A.E., et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282 (1998), 2261–2263.
113. 113 Izuhara, K., Arima, K., Yasunaga, S., IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies. Curr Drug Targets Inflamm Allergy 1 (2002), 263–269.
114. 114 Wenzel, S., Ford, L., Pearlman, D., et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368 (2013), 2455–2466.
115. 115 Fort, M.M., Cheung, J., Yen, D., et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15 (2001), 985–995.
116. 116 Hoyler, T., Klose Christoph, S.N., Souabni, A., et al. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity 37 (2012), 634–648.
117. 117 Wong, S.H., Walker, J.A., Jolin, H.E., et al. Rorα is essential for nuocyte development. Nat Immunol 13 (2012), 229–236.
118. 118 Doherty, T.A., Broide, D.H., Group 2 innate lymphoid cells: new players in human allergic diseases. J Investig Allergol Clin Immunol 25 (2015), 1–11 quiz 2p following.
119. 119 Mjosberg, J.M., Trifari, S., Crellin, N.K., et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 12 (2011), 1055–1062.
120. 120 Barnig, C., Cernadas, M., Dutile, S., et al. Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci Transl Med, 5, 2013, 174ra26.
121. 121 Monticelli, L.A., Sonnenberg, G.F., Abt, M.C., et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 12 (2011), 1045–1054.
122. 122 Salimi, M., Barlow, J.L., Saunders, S.P., et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med 210 (2013), 2939–2950.
123. 123 Bartemes, K.R., Kephart, G.M., Fox, S.J., Kita, H., Enhanced innate type 2 immune response in peripheral blood from patients with asthma. J Allergy Clin Immunol 134 (2014), 671–678.e4.
124. 124 Chang, J.E., Doherty, T.A., Baum, R., Broide, D., Prostaglandin D2 regulates human type 2 innate lymphoid cell chemotaxis. J Allergy Clin Immunol 133 (2014), 899–901.e3.
125. 125 Xue, L., Salimi, M., Panse, I., et al. Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J Allergy Clin Immunol 133 (2014), 1184–1194.
126. 126 Wilhelm, C., Hirota, K., Stieglitz, B., et al. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol 12 (2011), 1071–1077.
127. 127 Roediger, B., Kyle, R., Yip, K.H., et al. Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. Nat Immunol 14 (2013), 564–573.
128. 128 Madden, K.B., Urban, J.F. Jr., Ziltener, H.J., Schrader, J.W., Finkelman, F.D., Katona, I.M., Antibodies to IL-3 and IL-4 suppress helminth-induced intestinal mastocytosis. J Immunol 147 (1991), 1387–1391.
129. 129 Okumura, S., Kashiwakura, J., Tomita, H., et al. Identification of specific gene expression profiles in human mast cells mediated by toll-like receptor 4 and FcepsilonRI. Blood 102 (2003), 2547–2554.
130. 130 Balzar, S., Fajt, M.L., Comhair, S.A., et al. Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program. Am J Respir Crit Care Med 183 (2011), 299–309.
131. 131 Boyce, J.A., Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation. Immunol Rev 217 (2007), 168–185.
132. 132 Schwartz, L.B., Irani, A.M., Roller, K., Castells, M.C., Schechter, N.M., Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J Immunol 138 (1987), 2611–2615.
133. 133 Bentley, A.M., Hamid, Q., Robinson, D.S., et al. Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med 153 (1996), 551–556.
134. 134 Wenzel, S.E., Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 18 (2012), 716–725.
135. 135 Woodruff, P.G., Modrek, B., Choy, D.F., et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 180 (2009), 388–395.
136. 136 Modena, B.D., Tedrow, J.R., Milosevic, J., et al. Gene expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways. Am J Respir Crit Care Med 190 (2014), 1363–1372.
137. 137 Wu, W., Bleecker, E., Moore, W., et al. Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. J Allergy Clin Immunol 133 (2014), 1280–1288.
138. 138 Carroll, N.G., Mutavdzic, S., James, A.L., Distribution and degranulation of airway mast cells in normal and asthmatic subjects. Eur Respir J 19 (2002), 879–885.
139. 139 Dougherty, R.H., Sidhu, S.S., Raman, K., et al. Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma. J Allergy Clin Immunol 125 (2010), 1046–1053.e8.
140. 140 Bradley, B.L., Azzawi, M., Jacobson, M., et al. Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol 88 (1991), 661–674.
141. 141 Liesker, J.J., Ten Hacken, N.H., Rutgers, S.R., Zeinstra-Smith, M., Postma, D.S., Timens, W., Mast cell numbers in airway smooth muscle and PC20AMP in asthma and COPD. Respir Med 101 (2007), 882–887.
142. 142 Molderings, G.J., Brettner, S., Homann, J., Afrin, L.B., Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol, 4, 2011, 10.
143. 143 Molderings, G.J., Homann, J., Brettner, S., Raithel, M., Frieling, T., [Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options]. Dtsch Med Wochenschr 139 (2014), 1523–1534 quiz 35–8.
144. 144 Laprise, C., Boulet, L.P., Morissette, J., Winstall, E., Raymond, V., Evidence for association and linkage between atopy, airway hyper-responsiveness, and the beta subunit Glu237Gly variant of the high-affinity receptor for immunoglobulin E in the French-Canadian population. Immunogenetics 51 (2000), 695–702.
145. 145 Nagata, H., Mutoh, H., Kumahara, K., et al. Association between nasal allergy and a coding variant of the Fc epsilon RI beta gene Glu237Gly in a Japanese population. Hum Genet 109 (2001), 262–266.
146. 146 Rivera, J., Gilfillan, A.M., Molecular regulation of mast cell activation. J Allergy Clin Immunol 117 (2006), 1214–1225 quiz 26.
147. 147 Shirakawa, T., Li, A., Dubowitz, M., et al. Association between atopy and variants of the beta subunit of the high-affinity immunoglobulin E receptor. Nat Genet 7 (1994), 125–129.
148. 148 Meltzer, E.O., Hamilos, D.L., Hadley, J.A., et al. Rhinosinusitis: establishing definitions for clinical research and patient care. The J Allergy Clin Immunol 114:6 Suppl (2004), 155–212.
149. 149 Bhattacharyya, N., Incremental health care utilization and expenditures for chronic rhinosinusitis in the United States. Ann Otol Rhinol Laryngol 120 (2011), 423–427.
150. 150 Polzehl, D., Moeller, P., Riechelmann, H., Perner, S., Distinct features of chronic rhinosinusitis with and without nasal polyps. Allergy 61 (2006), 1275–1279.
151. 151 Kato, A., Immunopathology of chronic rhinosinusitis. Allergol Int 64 (2015), 121–130.
152. 152 Chaaban, M.R., Walsh, E.M., Woodworth, B.A., Epidemiology and differential diagnosis of nasal polyps. Am J Rhinol Allergy 27 (2013), 473–478.
153. 153 Van Zele, T., Claeys, S., Gevaert, P., et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 61 (2006), 1280–1289.
154. 154 Zhang, N., Van Zele, T., Perez-Novo, C., et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J Allergy Clin Immunol 122 (2008), 961–968.
155. 155 Mainz, J., Koitschev, A., Pathogenesis and management of nasal polyposis in cystic fibrosis. Curr Allergy Asthma Rep 12 (2012), 163–174.
156. 156 Mesolella, M., Cimmino, M., Cantone, E., et al. Nasal polyposis in atypical cystic fibrosis: a case report. Int J Pediatr Otorhinolaryngol Extra 5 (2010), 167–169.
157. 157 Gentile, V.G., Isaacson, G., Patterns of sinusitis in cystic fibrosis. Laryngoscope 106 (1996), 1005–1009.
158. 158 Sagel, S.D., Kapsner, R., Osberg, I., Sontag, M.K., Accurso, F.J., Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 164:8 Pt 1 (2001), 1425–1431.
159. 159 Balough, K., McCubbin, M., Weinberger, M., Smits, W., Ahrens, R., Fick, R., The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 20 (1995), 63–70.
160. 160 Khan, T.Z., Wagener, J.S., Bost, T., Martinez, J., Accurso, F.J., Riches, D.W., Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151 (1995), 1075–1082.
161. 161 Rowe-Jones, J.M., Shembekar, M., Trendell-Smith, N., Mackay, I.S., Polypoidal rhinosinusitis in cystic fibrosis: a clinical and histopathological study. Clin Otolaryngol Allied Sci 22 (1997), 167–171.
162. 162 Nepomuceno, I.B., Esrig, S., Moss, R.B., Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Chest 115 (1999), 364–370.
163. 163 Georgy, M.S., Peters, A.T., Chapter 7: nasal polyps. Allergy Asthma Proc 33:Suppl 1 (2012), S22–S23.
164. 164 Gevaert, P., Holtappels, G., Johansson, S.G., Cuvelier, C., Cauwenberge, P., Bachert, C., Organization of secondary lymphoid tissue and local IgE formation to Staphylococcus aureus enterotoxins in nasal polyp tissue. Allergy 60 (2005), 71–79.
165. 165 Slater, A., Smallman, L.A., Drake-Lee, A.B., Increase in epithelial mast cell numbers in the nasal mucosa of patients with perennial allergic rhinitis. J Laryngol Otol 110 (1996), 929–933.
166. 166 Ruhno, J., Howie, K., Anderson, M., et al. The increased number of epithelial mast cells in nasal polyps and adjacent turbinates is not allergy-dependent. Allergy 45 (1990), 370–374.
167. 167 Jacobson, M.R., Juliusson, S., Löwhagen, O., Balder, B., Kay, A.B., Durham, S.R., Effect of topical corticosteroids on seasonal increases in epithelial eosinophils and mast cells in allergic rhinitis: a comparison of nasal brush and biopsy methods. Clin Exp Allergy 29 (1999), 1347–1355.
168. 168 Braunstahl, G.J., Overbeek, S.E., Fokkens, W.J., et al. Segmental bronchoprovocation in allergic rhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am J Respir Crit Care Med 164 (2001), 858–865.
169. 169 Kawabori, S., Kanai, N., Tosho, T., Adachi, T., Existence of c-kit receptor-positive, tryptase-negative, IgE-negative cells in human allergic nasal mucosa: a candidate for mast cell progenitor. Int Arch Allergy Immunol 112 (1997), 36–43.
170. 170 Igarashi, Y., Goldrich, M.S., Kaliner, M.A., Irani, A.M., Schwartz, L.B., White, M.V., Quantitation of inflammatory cells in the nasal mucosa of patients with allergic rhinitis and normal subjects. J Allergy Clin Immunol 95 (1995), 716–725.
171. 171 Naclerio, R.M., Meier, H.L., Kagey-Sobotka, A., et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 128 (1983), 597–602.
172. 172 Schleimer, R.P., Fox, C.C., Naclerio, R.M., et al. Role of human basophils and mast cells in the pathogenesis of allergic diseases. J Allergy Clin Immunol 76:2 Pt 2 (1985), 369–374.
173. 173 Settipane, G.A., Nasal polyps: epidemiology, pathology, immunology, and treatment. Am J Rhinol 1 (1987), 119–126.
174. 174 Stevenson, D.D., Zuraw, B.L., Pathogenesis of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol 24 (2003), 169–188.
175. 175 Yamashita, T., Tsuji, H., Maeda, N., Tomoda, K., Kumazawa, T., Etiology of nasal polyps associated with aspirin-sensitive asthma. Rhinol Suppl 8 (1989), 15–24.
176. 176 Di Lorenzo, G., Drago, A., Esposito Pellitteri, M., et al. Measurement of inflammatory mediators of mast cells and eosinophils in native nasal lavage fluid in nasal polyposis. Int Arch Allergy Immunol 125 (2001), 164–175.
177. 177 Thaçi, D., Simpson, E.L., Beck, L.A., et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 387 (2016), 40–52.
178. 178 Landolina, N., Gangwar, R.S., Levi-Schaffer, F., Mast cells' integrated actions with eosinophils and fibroblasts in allergic inflammation: implications for therapy. Adv Immunol 125 (2015), 41–85.
179. 179 Hamilos, D.L., Leung, D.Y., Wood, R., et al. Evidence for distinct cytokine expression in allergic versus nonallergic chronic sinusitis. J Allergy Clin Immunol 96 (1995), 537–544.
180. 180 Chen, Y.S., Langhammer, T., Westhofen, M., Lorenzen, J., Relationship between matrix metalloproteinases MMP-2, MMP-9, tissue inhibitor of matrix metalloproteinases-1 and IL-5, IL-8 in nasal polyps. Allergy 62 (2007), 66–72.
181. 181 Yeo, N.K., Eom, D.W., Oh, M.Y., Lim, H.W., Song, Y.J., Expression of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 1 in nonrecurrent vs recurrent nasal polyps. Ann Allergy Asthma Immunol 111 (2013), 205–210.
182. 182 Lee, Y.M., Kim, S.S., Kim, H.A., et al. Eosinophil inflammation of nasal polyp tissue: relationships with matrix metalloproteinases, tissue inhibitor of metalloproteinase-1, and transforming growth factor-beta1. J Korean Med Sci 18 (2003), 97–102.
183. 183 Pawankar, R., Mast cells in allergic airway disease and chronic rhinosinusitis. Chem Immunol Allergy 87 (2005), 111–129.
184. 184 Pawankar, R., Lee, K.H., Nonaka, M., Takizawa, R., Role of mast cells and basophils in chronic rhinosinusitis. Clin Allergy Immunol 20 (2007), 93–101.
185. 185 Nonaka, M., Pawankar, R., Fukumoto, A., Ogihara, N., Sakanushi, A., Yagi, T., Induction of eotaxin production by interleukin-4, interleukin-13 and lipopolysaccharide by nasal fibroblasts. Clin Exp Allergy 34 (2004), 804–811.
186. 186 Pawankar, R., Mast cells in rhinitis. Watanabe, T., Timmerman, H., Yanai, K., (eds.) Histamine research in the new millennium, 2001, Elselvier Science, Amsterdam, 369–374.
187. 187 Takabayashi, T., Kato, A., Peters, A.T., et al. Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 130 (2012), 410–420.e5.
188. 188 Cao, P.P., Zhang, Y.N., Liao, B., et al. Increased local IgE production induced by common aeroallergens and phenotypic alteration of mast cells in Chinese eosinophilic, but not non-eosinophilic, chronic rhinosinusitis with nasal polyps. Clin Exp Allergy 44 (2014), 690–700.
189. 189 Bachert, C., Gevaert, P., van Cauwenberge, P., Staphylococcus aureus superantigens and airway disease. Curr Allergy Asthma Rep 2 (2002), 252–258.
190. 190 Shin, S.H., Ponikau, J.U., Sherris, D.A., et al. Chronic rhinosinusitis: an enhanced immune response to ubiquitous airborne fungi. J Allergy Clin Immunol 114 (2004), 1369–1375.
191. 191 Bachert, C., Gevaert, P., Holtappels, G., Johansson, S.G., van Cauwenberge, P., Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol 107 (2001), 607–614.
192. 192 Kramer, M.F., Burow, G., Pfrogner, E., Rasp, G., In vitro diagnosis of chronic nasal inflammation. Clin Exp Allergy 34 (2004), 1086–1092.
193. 193 Genovese, A., Borgia, G., Björck, L., et al. Immunoglobulin superantigen protein L induces IL-4 and IL-13 secretion from human Fc epsilon RI+ cells through interaction with the kappa light chains of IgE. J Immunol 170 (2003), 1854–1861.
194. 194 Genovese, A., Bouvet, J.P., Florio, G., Lamparter-Schummert, B., Björck, L., Marone, G., Bacterial immunoglobulin superantigen proteins A and L activate human heart mast cells by interacting with immunoglobulin E. Infect Immun 68 (2000), 5517–5524.
195. 195 Marshall, J.S., McCurdy, J.D., Olynych, T., Toll-like receptor-mediated activation of mast cells: implications for allergic disease?. Int Arch Allergy Immunol 132 (2003), 87–97.
196. 196 Sandig, H., Bulfone-Paus, S., TLR signaling in mast cells: common and unique features. Front Immunol, 3, 2012, 185.
197. 197 Malaviya, R., Georges, A., Regulation of mast cell-mediated innate immunity during early response to bacterial infection. Clin Rev Allergy Immunol 22 (2002), 189–204.
198. 198 Masuda, A., Yoshikai, Y., Aiba, K., Matsuguchi, T., Th2 cytokine production from mast cells is directly induced by lipopolysaccharide and distinctly regulated by c-Jun N-terminal kinase and p38 pathways. J Immunol 169 (2002), 3801–3810.
199. 199 Allakhverdi, Z., Comeau, M.R., Jessup, H.K., et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med 204 (2007), 253–258.
200. 200 Nagarkar, D.R., Poposki, J.A., Comeau, M.R., et al. Airway epithelial cells activate TH2 cytokine production in mast cells through IL-1 and thymic stromal lymphopoietin. J Allergy Clin Immunol 130 (2012), 225–232.e4.
201. 201 Rajan, J.P., Wineinger, N.E., Stevenson, D.D., White, A.A., Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol 135 (2015), 676–681.e1.
202. 202 Sladek, K., Szczeklik, A., Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Respir J 6 (1993), 391–399.
203. 203 Bochenek, G., Nagraba, K., Nizankowska, E., Szczeklik, A., A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 111 (2003), 743–749.
204. 204 Robuschi, M., Gambaro, G., Sestini, P., et al. Attenuation of aspirin-induced bronchoconstriction by sodium cromoglycate and nedocromil sodium. Am J Respir Crit Care Med 155 (1997), 1461–1464.
205. 205 Yoshida, S., Amayasu, H., Sakamoto, H., et al. Cromolyn sodium prevents bronchoconstriction and urinary LTE4 excretion in aspirin-induced asthma. Ann Allergy Asthma Immunol 80 (1998), 171–176.
206. 206 Narayanankutty, A., Resendiz-Hernandez, J.M., Falfan-Valencia, R., Teran, L.M., Biochemical pathogenesis of aspirin exacerbated respiratory disease (AERD). Clin Biochem 46 (2013), 566–578.
207. 207 Mastalerz, L., Nizankowska, E., Sladek, K., Szczeklik, A., Protective effects of prostaglandin E2 (PGE2) on airway obstruction induced by aspirin (ASA) in aspirin-intolerant asthmatics (AIA). European Respiratory Journal - Supplement [Internet], Suppl 18, 1994 [434s p.]. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/075/CN-00394075/frame.html.
208. 208 Sestini, P., Armetti, L., Gambaro, G., et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 153 (1996), 572–575.
209. 209 Szczeklik, A., Sladek, K., Dworski, R., et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med 154:6 Pt 1 (1996), 1608–1614.
210. 210 Ferreri, N.R., Howland, W.C., Stevenson, D.D., Spiegelberg, H.L., Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis 137 (1988), 847–854.
211. 211 Cahill, K.N., Raby, B.A., Zhou, X., et al. Impaired EP expression causes resistance to prostaglandin E in nasal polyp fibroblasts from subjects with AERD. Am J Respir Cell Mol Biol 54 (2016), 34–40.
212. 212 Moon, T.C., Campos-Alberto, E., Yoshimura, T., et al. Expression of DP2 (CRTh2), a prostaglandin D(2) receptor, in human mast cells. PLoS ONE, 9, 2014, e108595.
213. 2 in nasal congestion observed in a guinea pig model of allergic rhinitis. Int Arch Allergy Immunol 158 (2012), 359–368.
214. 214 Spik, I., Brenuchon, C., Angeli, V., et al. Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse. J Immunol 174 (2005), 3703–3708.
215. 215 Cahill, K.N., Bensko, J.C., Boyce, J.A., Laidlaw, T.M., Prostaglandin D(2): a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 135 (2015), 245–252.
216. 216 Irkec, M.T., Bozkurt, B., Molecular immunology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 12 (2012), 534–539.
217. 217 Ono, S.J., Abelson, M.B., Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 115 (2005), 118–122.
218. 218 Friedlaender, M.H., Ocular allergy. Curr Opin Allergy Clin Immunol 11 (2011), 477–482.
219. 219 Chigbu, D.I., The pathophysiology of ocular allergy: a review. Cont Lens Anterior Eye 32 (2009), 3–15 quiz 43–4.
220. 220 Hayashi, D., Li, D., Hayashi, C., Shatos, M., Hodges, R.R., Dartt, D.A., Role of histamine and its receptor subtypes in stimulation of conjunctival goblet cell secretion. Invest Ophthalmol Vis Sci 53 (2012), 2993–3003.
221. 221 Ohbayashi, M., Manzouri, B., Morohoshi, K., Fukuda, K., Ono, S.J., The role of histamine in ocular allergy. Adv Exp Med Biol 709 (2010), 43–52.
222. 222 Leonardi, A., Motterle, L., Bortolotti, M., Allergy and the eye. Clin Exp Immunol 153:Suppl 1 (2008), 17–21.
223. 223 Saban, D.R., Calder, V., Kuo, C.H., et al. New twists to an old story: novel concepts in the pathogenesis of allergic eye disease. Curr Eye Res 38 (2013), 317–330.
224. 224 Bonini, S., Bonini, S., Vecchione, A., Naim, D.M., Allansmith, M.R., Balsano, F., Inflammatory changes in conjunctival scrapings after allergen provocation in humans. J Allergy Clin Immunol 82:3 Pt 1 (1988), 462–469.
225. 225 Ueta, M., Nakamura, T., Tanaka, S., Kojima, K., Kinoshita, S., Development of eosinophilic conjunctival inflammation at late-phase reaction in mast cell-deficient mice. J Allergy Clin Immunol 120 (2007), 476–478.
226. 226 Leonardi, A., The central role of conjunctival mast cells in the pathogenesis of ocular allergy. Curr Allergy Asthma Rep 2 (2002), 325–331.
227. 227 Anderson, D.F., Zhang, S., Bradding, P., McGill, J.I., Holgate, S.T., Roche, W.R., The relative contribution of mast cell subsets to conjunctival TH2-like cytokines. Invest Ophthalmol Vis Sci 42 (2001), 995–1001.
228. 228 Cook, E.B., Stahl, J.L., Miller, S.T., et al. Isolation of human conjunctival mast cells and epithelial cells: tumor necrosis factor-alpha from mast cells affects intercellular adhesion molecule 1 expression on epithelial cells. Invest Ophthalmol Vis Sci 39 (1998), 336–343.
229. 229 Chen, J.J., Applebaum, D.S., Sun, G.S., Pflugfelder, S.C., Atopic keratoconjunctivitis: a review. J Am Acad Dermatol 70 (2014), 569–575.
230. 230 Leonardi, A., Di Stefano, A., Vicari, C., Motterle, L., Brun, P., Histamine H4 receptors in normal conjunctiva and in vernal keratoconjunctivitis. Allergy 66 (2011), 1360–1366.
231. 231 Bielory, L., Ghafoor, S., Histamine receptors and the conjunctiva. Curr Opin Allergy Clin Immunol 5 (2005), 437–440.
232. 232 Leonardi, A., DeFranchis, G., De Paoli, M., Fregona, I., Plebani, M., Secchi, A., Histamine-induced cytokine production and ICAM-1 expression in human conjunctival fibroblasts. Curr Eye Res 25 (2002), 189–196.
233. 233 Allansmith, M.R., Greiner, J.V., Baird, R.S., Number of inflammatory cells in the normal conjunctiva. Am J Ophthalmol 86 (1978), 250–259.
234. 234 Morgan, S.J., Williams, J.H., Walls, A.F., Church, M.K., Holgate, S.T., McGill, J.I., Mast cell numbers and staining characteristics in the normal and allergic human conjunctiva. J Allergy Clin Immunol 87:1 Pt 1 (1991), 111–116.
235. 235 Anderson, D.F., MacLeod, J.D., Baddeley, S.M., et al. Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leucocyte infiltration. Clin Exp Allergy 27 (1997), 1060–1066.
236. 236 Bieber, T., Atopic dermatitis. N Engl J Med 358 (2008), 1483–1494.
237. 237 Schultz Larsen, F., The epidemiology of atopic dermatitis. Monogr Allergy 31 (1993), 9–28.
238. 238 Hanifin, J.M., Reed, M.L., Eczema, P., Impact Working, G., A population-based survey of eczema prevalence in the United States. Dermatitis 18 (2007), 82–91.
239. 239 Otsuka, A., Kabashima, K., Mast cells and basophils in cutaneous immune responses. Allergy 70 (2015), 131–140.
240. 240 Boguniewicz, M., Leung, D., Atopic dermatitis. Adkinson, N.F. Jr., Bochner, B.S., Busse, W.W., et al. (eds.) Middleton's allergy: principles and practice, 7th ed, 2009, Mosby, Philadelphia, PA, 1083.
241. 241 Schneider, L., Tilles, S., Lio, P., et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 131 (2013), 295–299.e1–27.
242. 242 Kabashima, K., New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci 70 (2013), 3–11.
243. 243 Otsuka, A., Doi, H., Egawa, G., et al. Possible new therapeutic strategy to regulate atopic dermatitis through upregulating filaggrin expression. J Allergy Clin Immunol 133 (2014), 139–146.e1–10.
244. 244 Moniaga, C.S., Egawa, G., Kawasaki, H., et al. Flaky tail mouse denotes human atopic dermatitis in the steady state and by topical application with Dermatophagoides pteronyssinus extract. Am J Pathol 176 (2010), 2385–2393.
245. 245 Boguniewicz, B., Abrams, M., Fonacier, L., Atopic dermatitis and contact dermatitis. Adelman, D.C., Casale, T.B., Corren, J., (eds.) Manual of Allergy and Immunology, 5th ed, 2012, Lippincott Williams & Wilkins, Philadelphia, PA, 494.
246. 246 Krathen, R.A., Hsu, S., Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 53 (2005), 338–340.
247. 247 Lane, J.E., Cheyney, J.M., Lane, T.N., Kent, D.E., Cohen, D.J., Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54 (2006), 68–72.
248. 248 Gonzalez de Olano, D., de la Hoz Caballer, B., Nunez Lopez, R., et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 37 (2007), 1547–1555.
249. 249 Jarvikallio, A., Naukkarinen, A., Harvima, I.T., Aalto, M.L., Horsmanheimo, M., Quantitative analysis of tryptase- and chymase-containing mast cells in atopic dermatitis and nummular eczema. Br J Dermatol 136 (1997), 871–877.
250. 250 Irani, A.M., Sampson, H.A., Schwartz, L.B., Mast cells in atopic dermatitis*. Allergy 44 (1989), 31–34.
251. 251 Algermissen, B., Bauer, F., Schadendorf, D., Kropp, J.D., Czarnetzki, B.M., Analysis of mast cell subpopulations (MCT, MCTC) in cutaneous inflammation using novel enzyme-histochemical staining techniques. Exp Dermatol 3 (1994), 290–297.
252. 252 Oldhoff, J.M., Darsow, U., Werfel, T., et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 60 (2005), 693–696.
253. 253 Leung, D.Y., Boguniewicz, M., Howell, M.D., Nomura, I., Hamid, Q.A., New insights into atopic dermatitis. J Clin Invest 113:5 (2004), 651–657.
254. 254 Omoto, M., Gu, L.H., Sugiura, H., Uehara, M., Heterogeneity of dermal deposition of eosinophil granule major basic protein in acute lesions of atopic dermatitis. Arch Dermatol Res 292 (2000), 51–54.
255. 255 Boehme, S.A., Franz-Bacon, K., Chen, E.P., Ly, T.W., Kawakami, Y., Bacon, K.B., Murine bone marrow-derived mast cells express chemoattractant receptor-homologous molecule expressed on T-helper class 2 cells (CRTh2). Int Immunol 21 (2009), 621–632.
256. 256 Boehme, S.A., Chen, E.P., Franz-Bacon, K., et al. Antagonism of CRTH2 ameliorates chronic epicutaneous sensitization-induced inflammation by multiple mechanisms. Int Immunol 21 (2009), 1–17.
257. 257 Boehme, S.A., Franz-Bacon, K., Chen, E.P., et al. A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation. Int Immunol 21 (2009), 81–93.
258. 258 Satoh, T., Moroi, R., Aritake, K., et al. Prostaglandin D2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. J Immunol 177 (2006), 2621–2629.
259. 259 Gschwandtner, M., Mildner, M., Mlitz, V., et al. Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model. Allergy 68 (2013), 37–47.
260. 260 Ling, P., Ngo, K., Nguyen, S., et al. Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br J Pharmacol 142 (2004), 161–171.
261. 261 Hofstra, C.L., Desai, P.J., Thurmond, R.L., Fung-Leung, W.P., Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther 305 (2003), 1212–1221.
262. 262 Sonkoly, E., Muller, A., Lauerma, A.I., et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 117 (2006), 411–417.
263. 263 Raap, U., Wichmann, K., Bruder, M., et al. Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol 122 (2008), 421–423.
264. 264 Brandt, E.B., Sivaprasad, U., Th2 cytokines and atopic dermatitis. J Clin Cell Immunol 2 (2011), 1–25.
265. 265 Dillon, S.R., Sprecher, C., Hammond, A., et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 5 (2004), 752–760.
266. 266 Niyonsaba, F., Ushio, H., Hara, M., et al. Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. J Immunol 184 (2010), 3526–3534.
267. 267 Kopfnagel, V., Harder, J., Werfel, T., Expression of antimicrobial peptides in atopic dermatitis and possible immunoregulatory functions. Curr Opin Allergy Clin Immunol 13 (2013), 531–536.
268. 268 Liew, F.Y., Pitman, N.I., McInnes, I.B., Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 10 (2010), 103–110.
269. 269 Allakhverdi, Z., Smith, D.E., Comeau, M.R., Delespesse, G., Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 179 (2007), 2051–2054.
270. 270 Saluja, R., Khan, M., Church, M.K., Maurer, M., The role of IL-33 and mast cells in allergy and inflammation. Clin Transl Allergy, 5, 2015, 33.
271. 271 Shimizu, M., Matsuda, A., Yanagisawa, K., et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum Mol Genet 14 (2005), 2919–2927.
272. 272 Savinko, T., Matikainen, S., Saarialho-Kere, U., et al. IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J Invest Dermatol 132 (2012), 1392–1400.
273. 273 Meephansan, J., Tsuda, H., Komine, M., Tominaga, S., Ohtsuki, M., Regulation of IL-33 expression by IFN-gamma and tumor necrosis factor-alpha in normal human epidermal keratinocytes. J Invest Dermatol 132 (2012), 2593–2600.
274. 274 Imai, Y., Yasuda, K., Sakaguchi, Y., et al. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci U S A 110 (2013), 13921–13926.
275. 275 Rankin, A.L., Mumm, J.B., Murphy, E., et al. IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol 184 (2010), 1526–1535.
276. 276 Aronson, J.K., Ferner, R.E., Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 327 (2003), 1222–1225.
277. 277 Wheatley, L.M., Plaut, M., Schwaninger, J.M., et al. Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. J Allergy Clin Immunol 136 (2015), 262–271.e2.
278. 278 Blanca-López N, Torres M, Seoane M, et al. Immediate Hypersensitivity Reactions To Quinolones. J Allergy Clin Immunol. 127(2):AB191.
279. 279 Wang, H., Wang, H.S., Liu, Z.P., Agents that induce pseudo-allergic reaction. Drug Discov Ther 5 (2011), 211–219.
280. 280 Society TM. http://www.tmsforacure.org 2015.
281. 281 Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 105 (2010), 259–273.
282. 282 Guedes, A.G., Papich, M.G., Rude, E.P., Rider, M.A., Comparison of plasma histamine levels after intravenous administration of hydromorphone and morphine in dogs. J Vet Pharmacol Ther 30 (2007), 516–522.
283. 283 Woodall, H.E., Chiu, A., Weissman, D.E., Opioid allergic reactions #175. J Palliat Med 11 (2008), 1340–1341.
284. 284 Casale, T.B., Bowman, S., Kaliner, M., Induction of human cutaneous mast cell degranulation by opiates and endogenous opioid peptides: evidence for opiate and nonopiate receptor participation. J Allergy Clin Immunol 73 (1984), 775–781.
285. 285 Trescot, A.M., Datta, S., Lee, M., Hansen, H., Opioid pharmacology. Pain Physician 11:2 Suppl (2008), S133–S153.
286. 286 Liu, N.J., vonGizycki, H., Gintzler, A.R., Phospholipase Cbeta1 modulates pain sensitivity, opioid antinociception and opioid tolerance formation. Brain Res 1069 (2006), 47–53.
287. 287 Veien, M., Szlam, F., Holden, J.T., et al. Mechanisms of nonimmunological histamine and tryptase release from human cutaneous mast cells. Anesthesiology 92 (2000), 1074–1081.
288. 288 Gilfillan, A.M., Tkaczyk, C., Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 6 (2006), 218–230.
289. 289 Klinker, J.F., Seifert, R., Morphine and muscle relaxants are receptor-independent G-protein activators and cromolyn is an inhibitor of stimulated G-protein activity. Inflamm Res 46 (1997), 46–50.
290. 290 Levy, J.H., Brister, N.W., Shearin, A., et al. Wheal and flare responses to opioids in humans. Anesthesiology 70 (1989), 756–760.
291. 291 Grimbaldeston, M.A., Mast cell-MrgprB2: sensing secretagogues or a means to overreact. [quest] Immunol Cell Biol 93 (2015), 221–223.
292. 292 McNeil, B.D., Pundir, P., Meeker, S., et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 519 (2015), 237–241.
293. 293 Sivagnanam, S., Deleu, D., Red man syndrome. Critical Care 7 (2003), 119–120.
294. 294 Bruniera, F.R., Ferreira, F.M., Saviolli, L.R., et al. The use of vancomycin with its therapeutic and adverse effects: a review. Eur Rev Med Pharmacol Sci 19 (2015), 694–700.
295. 295 Horinouchi, Y., Abe, K., Kubo, K., Oka, M., Mechanisms of vancomycin-induced histamine release from rat peritoneal mast cells. Agents Actions 40 (1993), 28–36.
296. 296 Shuto, H., Sueyasu, M., Otsuki, S., et al. Potentiation of vancomycin-induced histamine release by muscle relaxants and morphine in rats. Antimicrob Agents Chemother 43 (1999), 2881–2884.
297. 297 Szebeni, J., Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216 (2005), 106–121.
298. 298 Banerji, A., Lax, T., Guyer, A., Hurwitz, S., Camargo, C.A., Long, A.A., Management of hypersensitivity reactions to carboplatin and paclitaxel in an outpatient oncology infusion center: a 5-year review. J Allergy Clin Immunol Pract 2 (2014), 428–433.
299. 299 White, A.A., Stevenson, D.D., Woessner, K.M., Simon, R.A., Approach to patients with aspirin hypersensitivity and acute cardiovascular emergencies. Allergy Asthma Proc 34 (2013), 138–142.
300. 300 Kowalski, M.L., Makowska, J.S., Blanca, M., et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs)—classification, diagnosis and management: review of the EAACI/ENDA and GA2LEN/HANNA. Allergy 66 (2011), 818–829.
301. 301 Sanchez-Borges, M., Capriles-Hulett, A., Caballero-Fonseca, F., NSAID-induced urticaria and angioedema: a reappraisal of its clinical management. Am J Clin Dermatol 3 (2002), 599–607.
302. 302 Sanchez-Borges, M., Caballero-Fonseca, F., Capriles-Hulett, A., Gonzalez-Aveledo, L., Aspirin-exacerbated cutaneous disease (AECD) is a distinct subphenotype of chronic spontaneous urticaria. J Eur Acad Dermatol Venereol 29 (2015), 698–701.
303. 303 Mastalerz, L., Setkowicz, M., Sanak, M., Szczeklik, A., Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol 113 (2004), 771–775.
304. 304 Setkowicz, M., Mastalerz, L., Podolec-Rubis, M., Sanak, M., Szczeklik, A., Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years. J Allergy Clin Immunol 123 (2009), 174–178.
305. 305 Settipane, R.A., Constantine, H.P., Settipane, G.A., Aspirin intolerance and recurrent urticaria in normal adults and children. Epidemiology and review. Allergy 35 (1980), 149–154.
306. 306 Gomes, E., Cardoso, M.F., Praça, F., Gomes, L., Mariño, E., Demoly, P., Self-reported drug allergy in a general adult Portuguese population. Clin Exp Allergy 34 (2004), 1597–1601.
307. 307 Steinke, J.W., Negri, J., Liu, L., Payne, S.C., Borish, L., Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease. J Immunol 193 (2014), 41–47.